Fameglow Holdings Forms HK$50 Million Anti-Ageing Joint Venture with Nagawa Pharmaceutical and Mirxes
I'm PortAI, I can summarize articles.
Fameglow Holdings Limited has formed a joint venture with NAGAWA Pharmaceutical and Mirxes, establishing a company in Hong Kong with a capital of HK$50 million. Fameglow will own 75%, NAGAWA 20%, and Mirxes 5%. The venture will focus on anti-ageing products in Hong Kong and selected Asia-Pacific countries. This is a discloseable transaction under GEM Listing Rules, not requiring shareholder approval.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments